GATA2 Gene: Structure, Function, and Clinical Significance
A master regulator of hematopoiesis and lymphatic development, implicated in immunodeficiency, leukemia, and lymphedema.
Gene Information Card
| Symbol | GATA2 |
|---|---|
| Full Name | GATA binding protein 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 3q21.3 (GRCh38) |
| NCBI Gene ID | 2624 ncbi.nlm.nih.gov/gene/2624 |
| Ensembl ID | ENSG00000179348 |
| UniProt ID | P23769 |
| OMIM ID | 137295 |
| HGNC ID | 4171 |
| Aliases | DCML, MONOMAC, NFE1B |
Description
The GATA2 gene encodes a zinc-finger transcription factor that is a master regulator of hematopoiesis, particularly for the maintenance and function of hematopoietic stem cells (HSCs), as well as for lymphatic and urogenital development. GATA2 is essential for the differentiation of myeloid and erythroid lineages, and it also regulates the expression of genes involved in endothelial and neural development. Germline mutations in GATA2 cause a spectrum of autosomal dominant disorders characterized by immunodeficiency, bone marrow failure, lymphedema, and predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Somatic mutations and altered expression of GATA2 are also implicated in various cancers, including leukemia and prostate cancer.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| MonoMAC syndrome / DCML deficiency | Loss-of-function mutations (e.g., frameshift, nonsense) leading to haploinsufficiency or dominant-negative effects, causing depletion of dendritic cells, monocytes, and natural killer cells, and progressive bone marrow failure. | ClinVar, OMIM (614172) |
| Emberger syndrome (primary lymphedema with myelodysplasia) | Heterozygous mutations (e.g., missense, splice-site) impairing GATA2 function, leading to lymphatic malformation and predisposition to MDS/AML. | OMIM (614038), ClinVar |
| Acute myeloid leukemia (AML) | Somatic mutations (e.g., missense in zinc-finger domains) or germline mutations causing loss of function, leading to disrupted hematopoiesis and leukemic transformation. GATA2 mutations are found in ~5-10% of AML cases, often with CEBPA mutations. | COSMIC, ClinVar, NCBI |
| Myelodysplastic syndrome (MDS) | Germline or somatic GATA2 mutations causing haploinsufficiency, leading to bone marrow failure and progression to AML. | ClinVar, COSMIC |
| Chronic myelomonocytic leukemia (CMML) | Somatic GATA2 mutations (e.g., missense) contributing to myeloproliferative/myelodysplastic phenotypes. | COSMIC |
| GATA2 deficiency syndrome (broader spectrum) | Various loss-of-function mutations (including intronic variants affecting regulatory elements) leading to a range of phenotypes: immunodeficiency, pulmonary alveolar proteinosis, and viral infections. | OMIM (614172), ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Bone Marrow | High (nTPM ~ 50-100) | High expression in hematopoietic stem/progenitor cells |
| Spleen | Moderate (nTPM ~ 20-50) | Expression in immune cells |
| Thymus | Moderate (nTPM ~ 20-50) | Expression in T-cell progenitors |
| Lymph Node | Moderate (nTPM ~ 20-50) | Expression in dendritic cells and lymphocytes |
| Kidney | Low (nTPM ~ 5-10) | Expression in renal epithelium |
| Prostate | Low (nTPM ~ 5-10) | Expression in epithelial cells |
| Brain | Low (nTPM ~ 1-5) | Expression in specific neuronal populations |
| Lung | Low (nTPM ~ 1-5) | Expression in endothelial cells |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K562 (CML) | High (nTPM ~ 100) | Erythroid/myeloid leukemia cell line; GATA2 is highly expressed |
| HL-60 (AML) | High (nTPM ~ 80) | Promyelocytic leukemia; GATA2 expression supports myeloid differentiation |
| THP-1 (Monocytic leukemia) | Moderate (nTPM ~ 50) | Monocytic cell line; GATA2 regulates monocyte genes |
| Jurkat (T-ALL) | Low (nTPM ~ 10) | T-cell leukemia; GATA2 expression is low but present |
| HeLa (Cervical cancer) | Low (nTPM ~ 5) | Epithelial cell line; GATA2 expression is minimal |
| MCF7 (Breast cancer) | Low (nTPM ~ 5) | Breast cancer; GATA2 expression is low |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1061C>T (p.Thr354Met) | Missense | Germline; rare | Loss of function; disrupts DNA binding; associated with MonoMAC syndrome |
| c.1017+2T>C (splice donor) | Splice-site | Germline; rare | Aberrant splicing leading to loss of function; Emberger syndrome |
| c.1186C>T (p.Arg396Trp) | Missense | Somatic; ~2% in AML | Loss of function; affects zinc-finger domain; associated with AML |
| c.1192C>T (p.Arg398Trp) | Missense | Somatic; ~1% in AML | Loss of function; affects DNA binding; seen in AML with CEBPA mutations |
| c.1081C>T (p.Arg361Cys) | Missense | Germline; rare | Loss of function; associated with GATA2 deficiency |
| c.932G>A (p.Trp311Ter) | Nonsense | Germline; rare | Premature truncation; haploinsufficiency; MonoMAC syndrome |
| c.1017G>A (splice donor) | Splice-site | Germline; rare | Splice defect; loss of function; Emberger syndrome |
| c.1187G>A (p.Arg396Gln) | Missense | Somatic; rare | Loss of function; zinc-finger domain; leukemia |
Mutation functional classification
Loss of Function (LOF)
Most GATA2 mutations are loss-of-function, leading to haploinsufficiency or dominant-negative effects. This impairs hematopoietic stem cell maintenance, causing cytopenias, immunodeficiency, and bone marrow failure.
Gain of Function (GOF)
Gain-of-function mutations are rare. Some somatic missense mutations (e.g., in the C-terminal zinc finger) may enhance transcriptional activity, but they are not well characterized. Overexpression of wild-type GATA2 can act as an oncogene in some contexts.
Dominant Negative (DN)
Certain missense mutations in the DNA-binding domain (e.g., p.Arg396Trp) can exert dominant-negative effects by binding to DNA but failing to activate transcription, interfering with wild-type GATA2 function.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Hematopoietic stem cell differentiation pathway (KEGG hsa04640)
• Transcriptional regulation of granulopoiesis (Reactome R-HSA-9616222)
• Erythropoietin signaling (Reactome R-HSA-9009391)
• Notch signaling pathway (Reactome R-HSA-157118)
• TGF-beta signaling pathway (Reactome R-HSA-2173793)
Protein Summary
GATA2 is a 480-amino acid transcription factor with two zinc-finger domains (N-terminal and C-terminal) that bind to the consensus DNA sequence (A/T)GATA(A/G). It regulates gene expression by recruiting co-activators and co-repressors. GATA2 is critical for the survival and proliferation of hematopoietic stem and progenitor cells, and it also controls the expression of key genes like RUNX1, TAL1, and FLI1. Post-translational modifications include phosphorylation and acetylation, which modulate its activity. Mutations in GATA2 lead to a haploinsufficient state, affecting multiple lineages and causing a wide clinical spectrum.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GATA2 Knockout HEK293 Cell Line | EDJ-KQ4687 | Human | 2624 | Details Get a Quote |
| GATA2 Knockout A-549 Cell Line | EDJ-KQ27390 | Human | 2624 | Details Get a Quote |
| GATA2 Knockout HCT 116 Cell Line | EDJ-KQ27391 | Human | 2624 | Details Get a Quote |
| GATA2 Knockout HeLa Cell Line | EDJ-KQ27392 | Human | 2624 | Details Get a Quote |
| GATA2 (c.1018-19C>T )Point Mutation in HAP1 Cell Line | EDC03496 | Human | 2624 | Details Get a Quote |
